Availability by country, dated, with primary sources

On the subject in the title: Availability by country, dated, with primary sources Working notes rather than a conclusion.

Documenting an access outcome, dated, because everything in this category expires.

As of May 2026, in my region, the position is as described below. I have linked the primary source rather than a summary of it, because the summaries are consistently a year behind.

If anyone can confirm or contradict this for their own region, please date your answer. An undated claim in this category is worse than no claim.

Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.

Language barriers: if you need to communicate with a supplier, clinician, or regulator in a language not your first language, misunderstanding is possible. Clarify when in doubt.

This follows post #11 rather than contradicting it.

Compounding in different countries: some countries allow pharmacy compounding under defined conditions; others do not. The rules are jurisdiction-specific and change.

Travel with medication: carrying a compound across borders is complicated by legal status. Documenting that it is prescribed and carrying proof reduces (but does not eliminate) risk.

Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.

Regulatory position dates: a regulatory position is only current as of when it was written. Rechecking is prudent, especially if you saw it months ago.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more predictive than theory.